• Explore /
  • Poster
  • / Results of multicenter phase II WSG Neo-Predict trial: Predictive markers for evaluation of response to neoadjuvant paclitaxel+trastuzumab+lapatinib in HER2-positive early breast cancer.

Results of multicenter phase II WSG Neo-Predict trial: Predictive markers for evaluation of response to neoadjuvant paclitaxel+trastuzumab+lapatinib in HER2-positive early breast cancer.

Abstract Poster

Authors

null

Christian Eichler

Krankenhaus Köln-Holweide, Cologne, Germany

Christian Eichler , Oleg Gluz , Ulrike Nitz , Matthias Christgen , Petra Krabisch , Reinhard Hackenberg , Markus Skrobol , Volker Möbus , Ronald Kates , Johannes Schumacher , Hans Heinrich Kreipe , Nadia Harbeck , Mathias Warm

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

2012-003679-21

Citation

J Clin Oncol 35, 2017 (suppl; abstr 582)

DOI

10.1200/JCO.2017.35.15_suppl.582

Abstract #

582

Poster Bd #

182

Abstract Disclosures

Similar Posters

First Author: Yuan Xia

First Author: Sherko Kümmel

First Author: Takashi Ishikawa

First Author: Ignacio Ortego